NASDAQ: BIIB

Biogen Inc.

Healthcare | Drug Manufacturers - General

Market prices for BIIB are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$9.30

Biogen Inc. (NASDAQ: BIIB) is a drug manufacturer. Figures from SEC EDGAR; updated 2026-10-19 17:04 UTC.

What Biogen Inc. does

Biogen is a global biopharmaceutical company that discovers, develops and delivers medicines for serious and complex diseases, with particular focus on neurology, specialized immunology and rare diseases. The company markets multiple medicines for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and amyotrophic lateral sclerosis, and has collaborations on Alzheimer's disease and postpartum depression treatments.

Summarized from Biogen Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	SCHEDULE 13G/A 2026-08-06
EPS (TTM)	$9.30

Revenue Trend

Annual Revenue · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-05

2026-10-05Chief Accounting OfficerTax withholding-8$1.8K
2026-10-05Chief Accounting OfficerRestricted Stock UnitOption exercise-27—
2026-10-05Chief Accounting OfficerRestricted Stock UnitAward985—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC18,217,239$3.94B+42.3%
BlackRock, Inc.15,985,736$3.45B+38.0%
PRIMECAP MANAGEMENT CO/CA/15,154,606$3.27B+2.7%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-01-15Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-10-30Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-09-12Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersLloyd MinorEstimatedSEC 8-K →

Company news

View all →

Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week
Benzinga2026-10-19
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Yahoo2026-10-19
A kidney transplant milestone has Wall Street excited about Biogen
Yahoo2026-10-17
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
Seeking Alpha Feed2026-10-16POS
Biogen-backed Estuary nabs $93M for liver disease gene therapy
BioPharma Dive2026-10-16

Questions this page answers

What does Biogen Inc. do?

When did BIIB last file with the SEC?

Biogen Inc.'s most recent SEC filing on record is a SCHEDULE 13G/A filed 2026-08-06. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 17:04 UTC. This page is also available as JSON at /api/data?ticker=BIIB and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BIIB and 5,000+ tickers.

Create a free account — keep BIIB

For your agent

GET /api/data?ticker=BIIB

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt